The FDA’s decision to remove certain screening and testing requirements for claseprubart trials has put Dianthus Therapeutics (DNTH) in focus, with renewed attention on the company’s autoimmune pipeline and clinical timelines.

The stock’s 1 day share price return of 2.7% decline and 7 day share price return of 4.9% decline contrast with a 30 day share price return of 7.7% and a 90 day share price return of 73.7%. The 1 year total shareholder return of about 3x suggests momentum has built over time as claseprubart has moved through the clinic and the FDA eased certain trial requirements.

If this FDA update has you rethinking where growth in healthcare could come from next, it may be worth scanning for other potential opportunities in 33 healthcare AI stocks

With Dianthus now valued around US$4.8b and the stock sitting below an average analyst price target, the key question is whether recent FDA momentum is already reflected in the share price or if the market is still underestimating future growth.

Preferred Price to Book Multiple of 9.6x: Is it justified?

Dianthus trades on a P/B of 9.6x, which prices the $87.39 last close at a premium to the broader US biotech group even after the recent pullback.

P/B compares the share price with the company’s net assets per share. It is often used for early stage biotech names where earnings are still negative and revenue is limited.

For Dianthus, the 9.6x P/B is well above the US biotech industry average of 2.4x. This implies investors are paying a higher price for each dollar of book value. However, that multiple is below the 20x peer average cited in the data, which suggests the market is giving the company a premium but not the most extreme one in its group.

Result: Price-to-book of 9.6x (OVERVALUED).

However, the story can change quickly if claseprubart data disappoints or if Dianthus needs to raise fresh capital, given current revenue of just US$2.04m and a net loss of US$162.34m.

Next Steps

Seeing both enthusiasm and caution in the story so far, you may want to move quickly and weigh the trade off yourself by reviewing the 1 key reward and 3 important warning signs

Ready to uncover your next investing angle?

If you stop with just one stock idea, you could miss other opportunities that better fit your goals, risk comfort and time horizon right now.

• Target long term compounding potential by scanning companies that combine quality with value using the 54 high quality undervalued stocks.
• Lock in income-focused ideas by reviewing companies in the 12 dividend fortresses that pair higher yields with resilience.
• Prioritise strength and staying power by checking stocks in the solid balance sheet and fundamentals stocks screener (42 results) that emphasise financial stability.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.